HIV & AIDS treatment in practice (HATIP) is a regular email newsletter for healthcare workers and community-based organisations on HIV treatment in resource-limited settings.

The world is starting to win the war against tuberculosis, but drug-resistant forms pose a new threat.

For several months, French hospitals have been receiving increasing numbers of patients from Eastern Europe with a multi-drug-resistant tuberculosis (MDR TB).

Mining companies are not doing enough to prevent the spread of diseases caused by mining, with 30% of all gold miners developing silicosis, which is fatal.

Dr Joel Keravec has come on board as GDF’s manager. Dr Keravec has 22 years of experience as a public health consultant and project manager in Latin America, Africa and Europe, for UNDP, UNESCO, and Management Sciences for Health (MSH), the French Ministry of Foreign Affairs, PAHO and the Brazilian Ministry of Health. His technical areas of expertise include pharmaceutical management, product quality assurance and international quality standards for drugs, quality testing for laboratories, selection of essential medicines for standardized TB treatment, improved policy and regulatory environments for essential medicines and improved product management information systems.

The rise in drug resistant infections is comparable to the threat of global warming, according to the chief medical officer for England.

A team of Australian researchers recently found that health officials might be able to more strategically implement control measures for tuberculosis by taking country of birth in local areas into account.

Doctors are concerned about the rising number of Russians infected with tuberculosis (TB). This number has more than doubled over the past 15 years, a senior healthcare official said on Thursday.

They called them the radium girls – five factory workers who sued a company that produced glow-in-the-dark radioactive paint because it knowingly exposed them to radiation poisoning.

A medication for multi-drug-resistant tuberculosis, bedaquiline, will soon become available in South Africa after being preliminarily cleared by the U.S. drug authority.